Stefania Paolillo
A5045700770- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiovascular and exercise physiology
- Cardiac pacing and defibrillation studies
- Cardiac Imaging and Diagnostics
- Lipoproteins and Cardiovascular Health
- Diabetes Treatment and Management
- Heart Rate Variability and Autonomic Control
- Mechanical Circulatory Support Devices
- Atrial Fibrillation Management and Outcomes
- Cardiac electrophysiology and arrhythmias
- Blood Pressure and Hypertension Studies
- Cardiovascular Effects of Exercise
- Pulmonary Hypertension Research and Treatments
- Hemodynamic Monitoring and Therapy
- Cardiac Structural Anomalies and Repair
- Cardiac Valve Diseases and Treatments
- Cardiovascular Disease and Adiposity
- Pharmaceutical Economics and Policy
- Advanced MRI Techniques and Applications
- Potassium and Related Disorders
- Cardiac Arrhythmias and Treatments
- Congenital Heart Disease Studies
- Cardiac Health and Mental Health
- Health Systems, Economic Evaluations, Quality of Life
Federico II University Hospital
2015-2025
University of Naples Federico II
2015-2025
Istituto Nazionale per le Ricerche Cardiovascolari
2024
SDN Istituto di Ricerca Diagnostica e Nucleare
2008-2023
Centro Cardiologico Monzino
2011-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2011-2023
Sapienza University of Rome
2023
Ospedale Monaldi
2022-2023
Clinica Mediterranea
2019-2022
University of Oslo
2022
Abstract Aims No data are available on early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in patients with acute coronary syndrome (ACS) the real world. This study investigates effects PCSK9i started at time ACS hospitalization lipid control and major cardiovascular (CV) events Methods results The outcome was percentage reaching LDL-C target <55 mg/dL first control. clinical incidence composite CV (all-cause death, non-fatal MI, stroke,...
Abstract Aims The last released European guidelines on the management of heart failure (HF) recommend in patients with chronic HF reduced ejection fraction (HFrEF) a pharmacological approach based four fundamental drugs to be rapidly implemented and then uptitrated modify disease progression. aim Optimization Therapy Italian Management Heart Failure (OPTIMA‐HF) registry is collect data outpatients different settings care. In present analysis, we report first analysis OPTIMA‐HF registry,...
It has been reported that epicardial adipose tissue (EAT) may affect myocardial autonomic function.The aim of this study was to explore the relationship between EAT and cardiac sympathetic nerve activity in patients with heart failure.In 110 systolic failure, we evaluated correlation echocardiographic thickness adrenergic assessed by (123)I-metaiodobenzylguanidine ((123)I-MIBG). The predictive value on denervation ((123)I-MIBG early late heart:mediastinum ratio single-photon emission...
Impaired parasympathetic and sympathetic nervous system activity have been demonstrated in patients with diabetes mellitus (DM) correlated worse prognosis. Few data are available on the effect of DM cardiac neuropathy heart failure (HF). The aim current study was to assess HF without DM.Patients severe (n = 75), 37) 38), 14 diabetic normal function underwent (123)I meta-iodobenzylguanidine scintigraphy from which early late heart-to-mediastinum (H/M) ratios were calculated. Clinical,...
Recent evidence supports the occurrence of multiple hormonal and metabolic deficiency syndrome (MHDS) in chronic heart failure (CHF). However, no large observational study has unequivocally demonstrated its impact on CHF progression outcome. The T.O.S.CA. (Trattamento Ormonale nello Scompenso CArdiaco; Hormone Treatment Heart Failure) Registry been specifically designed to test hypothesis that MHDS affects morbidity mortality patients.The is a prospective, multicentre, involving 19 Italian...